Healthcare >> Analyst Interviews >> July 14, 2003

Outlook For Large Cap Pharmaceuticals: Kenneth Nover – A.g. Edwards

KENNETH R. NOVER, Vice President of A.G. Edwards, covers the US-based global large-capitalization pharmaceutical companies. He also covers specialty pharmaceutical and biotechnology stocks. He joined A.G. Edwards in 1992. He has over 25 years of worldwide pharmaceutical and securities industry expertise including more than 12 years of financial and operating experience at Merck & Co., Inc., where he managed the financial reporting, planning and analysis of Merck's international operations. In addition, Mr. Nover served as its manager of operations for Japan, where he conducted financial analyses to ensure corporate goals and advised the line VP regarding acquisitions, licensing and competitive products and markets. Immediately prior to joining A.G. Edwards, Mr. Nover served as an analyst for a large Japanese securities firm and the American brokerage subsidiary of a major French bank. Mr. Nover earned a Master's degree in Business Administration with a concentration in Finance and a Bachelor of Arts degree, cum laude, from Rutgers University. While at Rutgers, Mr. Nover also distinguished himself with membership in Phi Beta Kappa. Profile
TWST: What has happened in the large cap pharmaceutical area this last

year and what is your current approach for that sector?

Mr. Nover: The group has been out of favor for a good year and a